Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Share News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Cash Shell Motif Bio Swings To Interim Loss On Derivative Liabilities

Mon, 12th Oct 2020 11:50

(Alliance News) - Motif Bio PLC on Monday said it swung to a loss in the first half of 2020 as it searches for a reverse takeover candidate.

The AIM-listed cash shell posted a loss for the half year ended June 30 of USD987,000 versus USD4.8 million profit a year prior.

The first half loss was primarily attributed to revaluation of derivative liabilities, which amounted to a loss of USD305,000 versus a gain of USD5.6 million.

The company said it is maintaining its focus on sourcing and completing an appropriate reverse takeover candidate in an effort to deliver value to shareholders.

This follows the company's re-organisation following shareholder approval at the end of 2019.

This has allowed Motif Bio to be unhindered by its previous obligations to its former operating subsidiary, Motif Biosciences Inc. This has given the the company the flexibility to pursue a reverse takeover candidate for the company.

Going forward, Motif Bio said it may require additional capital though the issuing of securities would mean "existing stockholders may experience significant dilution."

The company had USD800,000 cash at June 30.

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
17 Jul 2015 06:40

Motif Bio's Iclaprim Eligible For Incentives With New US Designation

Read more
23 Jun 2015 11:20

Motif Bio raises £22m via share placing

Biopharmaceutical company Motif Bio has raised £22m via a conditional share placing with institutional investors. The London-listed group said "the placing is conditional on securing shareholder approval and on a successful qualified infection disease product designation being given to its iclaprim

Read more
23 Jun 2015 09:28

Amphion Innovations Confident After Motif IPO, 2014 Asset Value Fall

Read more
23 Jun 2015 06:58

Motif Bio Raises GBP22 Million In Discounted Share Placing (ALLISS)

Read more
9 Jun 2015 08:27

Motif Bio Annual Loss Widened Slightly Ahead Of London IPO

Read more
1 Jun 2015 11:15

Motif Bio signs deal with leading clinical research organisation

A wholly-owned subsidiary of antibiotic developer Motif Bio has signed letters of intent and interim agreements with a leading global clinical research organisation (CRO). Motif has agreed to invest more than $0.95m under the agreements, which must be paid by the end of July. Under the agreements,

Read more
1 Jun 2015 07:23

Motif Bio Shares Up As It Moves Towards Iclaprim Clinical Trials

Read more
28 May 2015 09:47

Motif Bio Gets FDA Minutes Confirming Phase III Plans For Iclaprim

Read more
7 May 2015 09:12

Motif Bio Exploring Funding Options For Iclaprim Trials (ALLISS)

Read more
15 Apr 2015 07:31

LONDON MORNING BRIEFING: Next And Burberry Shares In Fashion

Read more
15 Apr 2015 07:10

Amphion Shares Up As Motif Bio Gets US FDA Approval For Iclaprim Trial

Read more
2 Apr 2015 11:46

Motif Bio makes AIM debut, seeks approval for Iclaprim treatment

Clinical stage biopharmaceutical group Motif Bio began trading on AIM on Thursday, after raising £2.8m in its initial public offering. The group, whose 44.09% of issued equity is owned by Amphion, placed shares at 20p each, said it had 64,238,442 ordinary shares in issue and a market capitalisation

Read more
2 Apr 2015 08:19

BCA Marketplace, Marshall Motor And Motif Bio Begin Trading (ALLIPO)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.